PharmChem, Inc.
PCHMOTCHealthcare
$3.75
+$0.01(+0.27%)
Market Cap$21950509
P/E Ratio—
52W High$3.98
52W Low$2.95
PharmChem, Inc. (PCHM) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
PCHM · earnings · updated Jun 8, 2026
Latest Earnings
Q3 FY2025Report Date: Aug 7, 2025EPS Actual
$0.04
Revenue
—
Fiscal Period
Q3 FY2025
FY ends December
Report Date
Aug 7, 2025
After Market Close
PCHM reports quarterly as a OTC-listed Medical - Diagnostics & Research company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.07
Rev. $15.39B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.07
Rev. Est.$15.39B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q2 FY2026 | May 7, 2026 | — | — | — | — | — | — |
| ◌ Q1 FY2026 | Mar 9, 2026 | — | — | — | — | — | — |
| — Q3 FY2025 | Aug 7, 2025 | — | $0.04 | — | — | — | — |
| — Q2 FY2025 | May 9, 2025 | — | $0.06 | — | — | — | — |
| — Q1 FY2025 | Mar 6, 2025 | — | $0.06 | — | $0.00B | — | — |
| — Q4 FY2024 | Nov 8, 2024 | — | $0.08 | — | — | — | — |
| — Q3 FY2024 | Aug 7, 2024 | — | $0.12 | — | $0.00B | — | — |
| — Q2 FY2024 | Apr 30, 2024 | — | $0.03 | — | $0.00B | — | — |
Q2 FY2026
May 7, 2026
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2026
Mar 9, 2026
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2025
Aug 7, 2025
EPS Actual
$0.04
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2025
May 9, 2025
EPS Actual
$0.06
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2025
Mar 6, 2025
EPS Actual
$0.06
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q4 FY2024
Nov 8, 2024
EPS Actual
$0.08
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2024
Aug 7, 2024
EPS Actual
$0.12
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q2 FY2024
Apr 30, 2024
EPS Actual
$0.03
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2024 | $1.54 | $1.54 | $1.54 | 1 |
| Q2 FY2024 | $1.34 | $1.34 | $1.34 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2024 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q3 FY2025 | Aug 7, 2025 | — | $3.71 | $3.71 | +0.00% |
| — Q2 FY2025 | May 9, 2025 | — | $2.97 | $2.97 | +0.00% |
| — Q1 FY2025 | Mar 6, 2025 | — | $3.15 | $3.15 | +0.00% |
| — Q4 FY2024 | Nov 8, 2024 | — | $3.40 | $3.40 | +0.00% |
| — Q3 FY2024 | Aug 7, 2024 | — | $2.85 | $3.55 | +24.56% |
| — Q2 FY2024 | Apr 30, 2024 | — | $2.75 | $2.75 | +0.00% |
| — Q1 FY2024 | Feb 27, 2024 | — | $3.00 | $3.00 | +0.00% |
| — Q4 FY2023 | Nov 2, 2023 | — | $2.45 | $2.70 | +10.20% |
Q3 FY2025+0.00%
Report Date
Aug 7, 2025
EPS Beat/Miss
—
Price Before
$3.71
Price After
$3.71
Q2 FY2025+0.00%
Report Date
May 9, 2025
EPS Beat/Miss
—
Price Before
$2.97
Price After
$2.97
Q1 FY2025+0.00%
Report Date
Mar 6, 2025
EPS Beat/Miss
—
Price Before
$3.15
Price After
$3.15
Q4 FY2024+0.00%
Report Date
Nov 8, 2024
EPS Beat/Miss
—
Price Before
$3.40
Price After
$3.40
Q3 FY2024+24.56%
Report Date
Aug 7, 2024
EPS Beat/Miss
—
Price Before
$2.85
Price After
$3.55
Q2 FY2024+0.00%
Report Date
Apr 30, 2024
EPS Beat/Miss
—
Price Before
$2.75
Price After
$2.75
Q1 FY2024+0.00%
Report Date
Feb 27, 2024
EPS Beat/Miss
—
Price Before
$3.00
Price After
$3.00
Q4 FY2023+10.20%
Report Date
Nov 2, 2023
EPS Beat/Miss
—
Price Before
$2.45
Price After
$2.70
Beat Rate0 / 8 quarters
Largest Move+24.56% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: PCHM ends December
PharmChem, Inc. (PCHM) most recently reported earnings on August 7, 2025 for Q3 FY2025, posting EPS of $0.04 (in line with the analyst consensus of —). The next PCHM earnings date is expected around September 1, 2026.
Each quarter, investors track PCHM earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. PCHM revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
PCHM's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
PCHM earnings · 4 questionsPharmChem, Inc.'s next earnings report is expected around September 1, 2026. PCHM typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; PCHM historically reports after market close (AMC).
PCHM earnings datewhen is PCHM earningsPCHM next earnings datewhen does PCHM report earningsPCHM earnings calendar
▸ Source: FMP · PharmChem, Inc. SEC filings · US GAAP · PharmChem, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026